Cited by 379Alzheimer's disease research and treatmentsGut microbiota and healthNeuroinflammation and Neurodegeneration Mechanisms

Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus

Open access
Zhao, Yuhai, Jaber, Vivian, Lukiw, Walter J.·2017·Frontiers in Cellular and Infection Microbiology

Abstract

Although the potential contribution of the human gastrointestinal (GI) tract microbiome to human health, aging and disease is becoming increasingly acknowledged, the molecular mechanics and signaling pathways of just how this is accomplished is not well understood. Major bacterial species of the GI tract, such as the abundant Gram-negative bacilli Bacteroides fragilis (B. fragilis) and Escherichia coli (E. coli), secrete a remarkably complex array of pro-inflammatory neurotoxins which, when released from the confines of the healthy GI tract, are pathogenic and highly detrimental to the homeostatic function of neurons in the central nervous system (CNS). For the first time here we report the presence of bacterial lipopolysaccharide (LPS) in brain lysates from the hippocampus and superior temporal lobe neocortex of Alzheimer’s disease (AD) brains. Mean LPS levels varied from 2-fold increases in the neocortex to 3-fold increases in the hippocampus, AD over age-matched controls, however some samples from advanced AD hippocampal cases exhibited up to a 26-fold increase in LPS over age-matched controls. This ‘Perspectives’ paper will further highlight some very recent research on GI tract microbiome signaling to the human CNS, and will update current findings that implicate GI tract microbiome-derived LPS as an important internal contributor to inflammatory degeneration in the CNS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcimb.2017.00318

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blood and brain endotoxin levels are elevated in Alzheimer's disease.

    “Blood and brain endotoxin levels are elevated in Alzheimer’s disease”

    From The endotoxin hypothesis of neurodegeneration (2019) · cites this paper as [78]

  • Brain endotoxin levels are increased two- or threefold in Alzheimer's disease patients, and endotoxin is also found in AD amyloid plaques.

    “Brain endotoxin levels are increased two- or threefold in AD patients [78, 79], and endotoxin is also found in AD amyloid plaques [79].”

    From The endotoxin hypothesis of neurodegeneration (2019) · cites this paper as [78]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhao, Y., Jaber, V., & Lukiw, W. J.
Affiliations
Louisiana State University (US)
Corresponding author
Lukiw, Walter J.
Venue
Frontiers in Cellular and Infection Microbiology
Published
2017-07-11
Volume
7
Pages
318-318
ISSN
2235-2988 (ISSN-L)
OpenAlex
W2735753950
Cited by
379
References
88
Citations by year
2026: 23 · 2025: 35 · 2024: 45 · 2023: 42 · 2022: 61 · 2021: 69 · 2020: 42 · 2019: 36 · 2018: 20 · 2017: 6
FWCI
3.49
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
NIH (NEI EY006311, NIA AG18031, NIA AG038834)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, gut microbiota, lipopolysaccharide, hippocampus, neocortex, Bacteroides fragilis, Escherichia coli, neuroinflammation, neurotoxins, gut-brain axis
MeSH terms
Gastrointestinal Microbiome, Alzheimer Disease, Bacteroides fragilis, Escherichia coli, Hippocampus, Humans, Lipopolysaccharides, Neocortex, Gastrointestinal Tract

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review